Targeted therapy in patients with poor-prognosis renal cell carcinoma
| Autor: | B. Ya. Alekseev, A. S. Kalpinskiy, A. A. Mukhomed’yarova, K. M. Nyushko, A. D. Kaprin |
|---|---|
| Jazyk: | ruština |
| Rok vydání: | 2017 |
| Předmět: |
Oncology
medicine.medical_specialty Poor prognosis medicine.drug_class Urology medicine.medical_treatment tyrosine-kinase inhibitor urologic and male genital diseases metastatic renal cell carcinoma Tyrosine-kinase inhibitor Targeted therapy Renal cell carcinoma Internal medicine temsirolimus Overall survival Medicine Radiology Nuclear Medicine and imaging Patient group business.industry poor prognosis medicine.disease targeted therapy Temsirolimus Nephrology Surgery torisel business medicine.drug |
| Zdroj: | Onkourologiâ, Vol 13, Iss 2, Pp 49-55 (2017) |
| ISSN: | 1996-1812 1726-9776 |
| Popis: | The majority of patients with metastatic renal cell carcinoma (mRCC) are in the groups of favorable or moderate prognosis per the MSKCC (MemorialSloan-KetteringCancerCenter) criteria, but in 20–30 % of poor-prognosis patients aggressive, rapidly progressing mRCC is observed. Despite improved prognosis in mRCC patients due to targeted therapy, this patient group remains hard to treat with overall survival 6 months) was higher in the temsirolimus (32.1 %) and combination (28.1 %) groups compared to the IFN-α group (15.5 %; р |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|